Emcure Pharmaceuticals Ltd. (EMCURE) Share Price Hits 52-Week High
- July 31, 2026
- Posted by: Harsh Piplani
- Category: News
Emcure Pharmaceuticals Ltd. Share Price reached a fresh 52-week high of Rs 1959.15, rising 2.35% today, with a market cap of Rs 36,130.27 crore.
Emcure Pharmaceuticals Ltd. Share Price has reached a fresh 52-week high of Rs 1959.15, marking a 2.35% increase from the previous close of Rs 1909.95. The company’s market capitalisation now stands at Rs 36,130.27 crore. This milestone highlights the stock’s recent momentum in the market, drawing investor attention. The healthcare sector, where Emcure operates, remains a significant focus for investors, contributing to the stock’s positive performance. Univest continues to monitor Emcure Pharmaceuticals Ltd. Share Price for further developments.
Emcure Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,954.8 |
| Previous Close | Rs 1,909.95 |
| Today's Change | +Rs 44.85 (+2.35%) |
| Day Open | Rs 1,934.35 |
| Fresh 52-Week High | Rs 1,959.15 |
| Day Low | Rs 1,905 |
| Current Volume | 1,664 |
| Turnover | Rs 0.33 crore |
| Market Capitalisation | Rs 36,130.27 crore |
Emcure Pharmaceuticals Ltd. (EMCURE) traded at Rs 1,954.8. versus the previous close of Rs 1,909.95, a rise of 2.35%. The stock opened at Rs 1,934.35, reached Rs 1,959.15, touched Rs 1,905. Reported volume was 1,664.
Today, Emcure Pharmaceuticals Ltd. opened at Rs 1934.35 and reached a high of Rs 1959.15, setting a new 52-week high. The stock’s low for the day was Rs 1905, with a turnover of Rs 0.33 crore. The current volume of 1664 indicates active trading, although it remains a small fraction of the company’s overall market cap. The 2.35% rise from the previous close underscores the stock’s upward momentum, capturing market interest.
Emcure Pharmaceuticals Ltd. (EMCURE) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 36,130.27 crore |
| P/E Ratio | 39.17x |
| P/B Ratio | 7.93x |
| ROE | 28.21% |
| ROCE | 26.35% |
Emcure Pharmaceuticals Ltd. was valued at a P/E ratio of 39.17x, a P/B ratio of 7.93x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 39.17x |
| Benchmark Median P/E | 20.13x |
| Benchmark Average P/E | 73.73x |
| Benchmark P/E Range | 0x to 3,417.8x |
| Company P/B Ratio | 7.93x |
| Benchmark Median P/B | 1.92x |
| Company ROE | 28.21% |
| Benchmark Median ROE | 10.73% |
| Company ROCE | 26.35% |
| Benchmark Median ROCE | 13.2% |
| Company Market Capitalisation | Rs 36,130.27 crore |
| Benchmark Median Market Cap | Rs 140.91 crore |
Emcure Pharmaceuticals Ltd. (EMCURE) is classified under sector: Healthcare.
Emcure Pharmaceuticals Ltd. (EMCURE) has a P/E ratio of 39.17x, which is above the benchmark median of 20.13x, a difference of +94.59%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Emcure Pharmaceuticals Ltd. (EMCURE) has a ROE of 28.21%, which is above the benchmark median of 10.73%, a difference of +162.91%. Emcure Pharmaceuticals Ltd. (EMCURE) has a ROCE of 26.35%, which is above the benchmark median of 13.2%, a difference of +99.62%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd. | KPL | 2,700.98 | 39.17 | 7.93 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,475.7 | 58.88 | 9.32 | 18.65 | 22.17 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,439.14 | 165.82 | 3.06 | 13.9 | 12.97 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,424.44 | 34.59 | 7 | -2.6 | 16.92 |
| Venus Remedies Ltd. | VENUSREM-BE | 2,150.28 | 17.79 | 3.01 | 9.85 | 7.89 |
Emcure Pharmaceuticals Ltd. (EMCURE) has a P/E ratio of 39.17x compared with the displayed peer median of 39.17x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Emcure Pharmaceuticals Ltd. (EMCURE) has a market capitalisation of Rs 36,130.27 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Emcure Pharmaceuticals Ltd.
- Emcure Pharmaceuticals Ltd. Share Price reached a fresh 52-week high, indicating strong market momentum.
- The company’s fundamentals, including high ROE and ROCE, highlight its financial strength.
- Emcure’s premium valuation reflects investor confidence in its growth prospects.
- The healthcare sector’s performance supports Emcure’s market position.
About Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. is a leading player in the healthcare sector, focusing on the development, manufacturing, and marketing of a broad range of pharmaceutical products. The company operates in various therapeutic segments, providing innovative solutions to healthcare challenges. Emcure’s commitment to quality and innovation has established it as a trusted name in the industry, serving both domestic and international markets. With a strong pipeline and a focus on research and development, Emcure continues to expand its product offerings and market reach.
Track Emcure Pharmaceuticals Ltd. Share Price on Univest
Use Emcure Pharmaceuticals Ltd. (EMCURE) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Emcure Pharmaceuticals Ltd. Share Price, technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay informed with the latest data and analysis to make informed investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Emcure Pharmaceuticals Ltd.?
Ans. The current share price of Emcure Pharmaceuticals Ltd. is Rs 1954.8, marking a 2.35% increase from the previous close. The stock moved 2.35% during the session. The intraday range extended from Rs 1,905 to Rs 1,959.15.
What is Emcure Pharmaceuticals Ltd.'s market capitalisation?
Ans. Emcure Pharmaceuticals Ltd.'s market capitalisation is Rs 36,130.27 crore, reflecting its significant presence in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 39.17x. ROE is 28.21% and ROCE is 26.35%.
How does Emcure Pharmaceuticals Ltd.'s P/E ratio compare to the sector median?
Ans. Emcure Pharmaceuticals Ltd.'s P/E ratio of 39.17 is above the sector median of 20.13, indicating a relatively higher valuation. The company trades at a P/E ratio of 39.17x. Its P/B ratio is 7.93x.
What is the 52-week high of Emcure Pharmaceuticals Ltd.?
Ans. The 52-week high of Emcure Pharmaceuticals Ltd. is Rs 1959.15, achieved on 31 July 2026. The stock moved 2.35% during the session. The intraday range extended from Rs 1,905 to Rs 1,959.15.
How does Emcure Pharmaceuticals Ltd.'s ROE compare to the sector median?
Ans. Emcure Pharmaceuticals Ltd.'s ROE of 28.21% is significantly higher than the sector median of 10.73%, showcasing strong profitability. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.73%.
What is Emcure Pharmaceuticals Ltd.'s P/B ratio?
Ans. Emcure Pharmaceuticals Ltd.'s P/B ratio is 7.93, which is above the sector median of 1.92, indicating a premium valuation. The company trades at a P/E ratio of 39.17x. Its P/B ratio is 7.93x.
Who are Emcure Pharmaceuticals Ltd.'s peers?
Ans. Emcure Pharmaceuticals Ltd.'s peers include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., and Sai Parenteral's Ltd., among others. Comparable listed companies include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Sai Parenteral's Ltd.
What is Emcure Pharmaceuticals Ltd.'s ROCE?
Ans. Emcure Pharmaceuticals Ltd.'s ROCE is 26.35%, indicating efficient capital use and strong operational performance. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.73%. The relevant peer median ROCE is 13.2%.
